Literature DB >> 23958486

Cannabis users have higher premorbid IQ than other patients with first onset psychosis.

Laura Ferraro1, Manuela Russo, Jennifer O'Connor, Benjamin D R Wiffen, Maria Aurora Falcone, Lucia Sideli, Poonam Gardner-Sood, Simona Stilo, Antonella Trotta, Paola Dazzan, Valeria Mondelli, Heather Taylor, Bess Friedman, Hannah Sallis, Caterina La Cascia, Daniele La Barbera, Anthony S David, Abraham Reichenberg, Robin M Murray, Marta Di Forti.   

Abstract

BACKGROUND: A number of studies have reported that patients with psychosis who use cannabis have better cognitive performance than those who do not. This is surprising as cannabis can impair cognition in healthy subjects. An obvious question is whether the better current performance of psychotic patients who have used cannabis is a reflection of their having a higher premorbid IQ than those psychotic patients who haven't used cannabis. AIM: In a sample of patients at their first episode of psychosis, we tested the hypothesis that patients who smoked cannabis would have a higher premorbid IQ than patients who did not.
METHODOLOGY: 279 participants (119 patients and 160 healthy controls) were assessed in order to obtain current and premorbid IQ measures and detailed information on cannabis use. We examined the association between cannabis use and both premorbid and current IQ in patients and controls.
RESULTS: Patients who had ever smoked cannabis had significantly higher current (p<.001) and premorbid IQ (p=.004) compared to patients who had never used cannabis. This difference was not found among controls.
CONCLUSIONS: These findings suggest that the better cognitive performance of patients with their first episode of psychosis who have used cannabis compared with those who haven't is due to the better premorbid IQ of the former.
© 2013.

Entities:  

Keywords:  Cannabis; Cognition; First Episode of Psychosis (FEP); IQ; Premorbid IQ; Risk of psychosis; Schizophrenia; Substance use

Mesh:

Year:  2013        PMID: 23958486     DOI: 10.1016/j.schres.2013.07.046

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis.

Authors:  Marco Colizzi; Conrad Iyegbe; John Powell; Gianluca Ursini; Annamaria Porcelli; Aurora Bonvino; Paolo Taurisano; Raffaella Romano; Rita Masellis; Giuseppe Blasi; Craig Morgan; Katherine Aitchison; Valeria Mondelli; Sonija Luzi; Anna Kolliakou; Anthony David; Robin M Murray; Alessandro Bertolino; Marta Di Forti
Journal:  Schizophr Bull       Date:  2015-03-31       Impact factor: 9.306

2.  Evaluating the relationship between cannabis use and IQ in youth and young adults at clinical high risk of psychosis.

Authors:  Lisa Buchy; Larry J Seidman; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; William Stone; Ming T Tsuang; Elaine F Walker; Scott W Woods; Carrie E Bearden; Daniel H Mathalon; Jean Addington
Journal:  Psychiatry Res       Date:  2015-11-25       Impact factor: 3.222

3.  Cannabis use and cognitive function in first episode psychosis: differential effect of heavy use.

Authors:  Christian Núñez; Susana Ochoa; Elena Huerta-Ramos; Iris Baños; Ana Barajas; Montserrat Dolz; Bernardo Sánchez; Núria Del Cacho; Judith Usall
Journal:  Psychopharmacology (Berl)       Date:  2015-12-01       Impact factor: 4.530

4.  Compared to high and low cannabis use, moderate use is associated with fewer cognitive deficits in psychosis.

Authors:  Ashley M Schnakenberg Martin; Kelsey A Bonfils; Beshaun J Davis; Elizabeth A Smith; Kelly Schuder; Paul H Lysaker
Journal:  Schizophr Res Cogn       Date:  2016-10-10

5.  Hemispheric language asymmetry in first episode psychosis and schizotypy: the role of cannabis consumption and cognitive disorganization.

Authors:  Daniela A Herzig; Sarah Sullivan; Glyn Lewis; Rhiannon Corcoran; Richard Drake; Jonathan Evans; David Nutt; Christine Mohr
Journal:  Schizophr Bull       Date:  2014-12-27       Impact factor: 9.306

Review 6.  The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia.

Authors:  David W Volk; David A Lewis
Journal:  Biol Psychiatry       Date:  2015-06-19       Impact factor: 13.382

7.  Cannabis-related working memory deficits and associated subcortical morphological differences in healthy individuals and schizophrenia subjects.

Authors:  Matthew J Smith; Derin J Cobia; Lei Wang; Kathryn I Alpert; Will J Cronenwett; Morris B Goldman; Daniel Mamah; Deanna M Barch; Hans C Breiter; John G Csernansky
Journal:  Schizophr Bull       Date:  2013-12-15       Impact factor: 9.306

8.  Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use.

Authors:  Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti
Journal:  Schizophr Bull       Date:  2020-04-10       Impact factor: 9.306

9.  Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis.

Authors:  Robin M Murray; Harriet Quigley; Diego Quattrone; Amir Englund; Marta Di Forti
Journal:  World Psychiatry       Date:  2016-10       Impact factor: 49.548

10.  Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.

Authors:  Diego Quattrone; Laura Ferraro; Giada Tripoli; Caterina La Cascia; Harriet Quigley; Andrea Quattrone; Hannah E Jongsma; Simona Del Peschio; Giusy Gatto; Charlotte Gayer-Anderson; Peter B Jones; James B Kirkbride; Daniele La Barbera; Ilaria Tarricone; Domenico Berardi; Sarah Tosato; Antonio Lasalvia; Andrei Szöke; Celso Arango; Miquel Bernardo; Julio Bobes; Cristina Marta Del Ben; Paulo Rossi Menezes; Pierre-Michel Llorca; Jose Luis Santos; Julio Sanjuán; Andrea Tortelli; Eva Velthorst; Lieuwe de Haan; Bart P F Rutten; Michael T Lynskey; Tom P Freeman; Pak C Sham; Alastair G Cardno; Evangelos Vassos; Jim van Os; Craig Morgan; Ulrich Reininghaus; Cathryn M Lewis; Robin M Murray; Marta Di Forti
Journal:  Psychol Med       Date:  2020-03-18       Impact factor: 7.723

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.